- FDA Approves another Bisphosphonate for Osteoporosis, but Cautions Exist
- Takeda Concealed Actos Side Effects, Whistle-Blower Suit Claims
- Federal Court Begins the Selection Process for Initial Avandia Suits
- 2012 Nursing Home Rankings Indentifies Few Outstanding Facilities
- DES Linked to Serious Health Issues for Multiple Generations
- Study Discovers Multaq Use Doubles Chances of Death From Heart Disease
- Despite Risks, FDA Approves Generic Form of Yaz
- Federal Lawsuits Over Cancer Causing Diabetes Drug Actos Consolidated
- Breast Cancer and the Environment: A Life Course Approach
- Breast cancer following diethylstilbestrol exposure in utero: insights from a tragedy
- Smoking Cessation Drug May Increase Chance of Cardiovascular Adverse Event
- Popular Diabetes Medication’s Link to Urinary Bladder Cancer Raises Concern
- DES Daughters Drug Litigation Proceeds in Boston Federal District Court
- New Concerns Arise Over Potentially Dangerous Osteoporosis Drugs
- Infertility among Women Exposed Prenatally to Diethylstilbestrol
- Adverse Health Outcomes in Women Exposed In Utero to Diethylstilbestrol
- Accutane Robertson Survey
- Accutane One Month Report
- Accutane NDA Report
- Accutane Trial Cited
- Washingtonian Magazine Profiles Aaron M. Levine
- Washington's Ten Most Feared Lawyers
- DES Premature Grandchildren
- In Utero Exposure to Diethylstilbestrol (DES) or Bisphenol-A (BPA) Increases EZH2 Expression in the Mammary Gland: An Epigenetic Mechanism Linking Endocrine Disruptors to Breast Cancer









